FKBPL Monoclonal Antibody

Category: Antibodies
Catalog
E-AB-27601
(Ships in 5-10 business days)

Questions? Contact us

Call (800) 832-2611

arp-guarantee
- +
$0.00
More Information
Product Name FKBPL Monoclonal Antibody
Description FKBPL,also named as DIR1,NG7 and WISp39,has similarity to the immunophilin protein family,which plays a role in immunoregulation and basic cellular processes involving protein folding and trafficking. This protein is thought to have a potential role in the induced radioresistance,probably by increasing the rate of DNA repair in cells exposed to X rays. Also it appears to have some involvement in general stress response in the control of the cell cycle. It regulates p21 protein stability by binding to Hsp90 and p21. Breast cancer cells stably overexpressing FKBPL became dependent on estrogen for their growth and were dramatically more sensitive to the antiestrogens tamoxifen and fulvestrant,whereas FKBPL knockdown reverses this phenotype. FKBPL is an estrogen-inducible gene that acts as a cochaperone in ER_/Hsp90 molecular complexes; furthermore,FKBPL levels may be both a prognostic indicator and determinant of response to endocrine therapy.
Synonyms DIR1,FK506 binding protein like,FKBPL,NG7,WISP39
Host Mouse
Clone 170
Immunogen Fusion protein of FKBPL
Isotype IgG1
Reactivity Human, Mouse
Applications ELISA, WB
Form PBS with 0.1% sodium azide, 50% glycerol, PH7.3
Uniprot Q9UIM3
Background FKBPL,also named as DIR1,NG7 and WISp39,has similarity to the immunophilin protein family,which plays a role in immunoregulation and basic cellular processes involving protein folding and trafficking. This protein is thought to have a potential role in the induced radioresistance,probably by increasing the rate of DNA repair in cells exposed to X rays. Also it appears to have some involvement in general stress response in the control of the cell cycle. It regulates p21 protein stability by binding to Hsp90 and p21. Breast cancer cells stably overexpressing FKBPL became dependent on estrogen for their growth and were dramatically more sensitive to the antiestrogens tamoxifen and fulvestrant,whereas FKBPL knockdown reverses this phenotype. FKBPL is an estrogen-inducible gene that acts as a cochaperone in ER_/Hsp90 molecular complexes; furthermore,FKBPL levels may be both a prognostic indicator and determinant of response to endocrine therapy.
Supplier Elabscience

All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.